Santen Pharmaceutical Co., Ltd.
SNPHY · OTC
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Market Cap | $495,028,338 | $521,308,696 | $435,025,736 | $485,365,604 |
| - Cash | $92,997,000 | $94,582,000 | $57,903,000 | $83,014,000 |
| + Debt | $34,229,000 | $35,158,000 | $36,207,000 | $32,932,000 |
| Enterprise Value | $436,260,338 | $461,884,696 | $413,329,736 | $435,283,604 |
| Revenue | $300,004,000 | $301,965,000 | $279,037,000 | $266,257,000 |
| % Growth | -0.6% | 8.2% | 4.8% | – |
| Gross Profit | $171,027,000 | $178,709,000 | $166,087,000 | $156,586,000 |
| % Margin | 57% | 59.2% | 59.5% | 58.8% |
| EBITDA | $59,009,000 | $50,716,000 | $12,949,000 | $52,930,000 |
| % Margin | 19.7% | 16.8% | 4.6% | 19.9% |
| Net Income | $36,256,000 | $26,642,000 | -$14,948,000 | $27,218,000 |
| % Margin | 12.1% | 8.8% | -5.4% | 10.2% |
| EPS Diluted | 103.68 | 72.37 | -38.58 | 67.97 |
| % Growth | 43.3% | 287.6% | -156.8% | – |
| Operating Cash Flow | $60,928,000 | $72,649,000 | $37,147,000 | $46,043,000 |
| Capital Expenditures | -$6,662,000 | -$10,687,000 | -$24,588,000 | -$35,841,000 |
| Free Cash Flow | $54,266,000 | $61,962,000 | $12,559,000 | $10,202,000 |